The Biomarker Qualification Program was established to support the Center for Drug Evaluation and Research’s (CDER's) work with external stakeholders to develop biomarkers that aid in the drug development process. Through the FDA’s Biomarker Qualification Program, you may request regulatory qualification of a biomarker for a particular context of use in drug development.
Biomarkers can be used in a variety of settings, including basic research, drug development, and clinical practice. The Biomarker Qualification Program focuses on biomarkers used in drug development. Once a biomarker is qualified, it can be used in any drug development program under the context for which it obtained qualification.
The Biomarker Qualification Program is one of the Drug Development Tools (DDT) Qualification Programs created by CDER to provide a framework for development and regulatory acceptance of scientific tools for use in drug development programs.
About FDA Biomarker Qualification video transcript
The goals of the CDER Biomarker Qualification Program are to:
- Provide a framework for development and regulatory acceptance of biomarkers for use in drug development
- Facilitate integration of qualified biomarkers into the regulatory review process
- Encourage the identification of new and emerging biomarkers for evaluation and use in regulatory decision making
- Support outreach to stakeholders to encourage biomarker development
A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.
For clarifications of important definitions and explanations of some of the relationships among terms, review the BEST (Biomarkers, EndpointS, and other Tools) Resource and the BEST Resource Fact Sheet.
Biomarkers can provide valuable information at various stages of drug development. They have the potential to:
- Reduce the time required to complete clinical trials
- Reduce the sample sizes required to achieve statistical significance
- Provide valuable information that could reduce uncertainty in regulatory decisions
Why qualify a biomarker through the CDER Biomarker Qualification Program?
A qualified biomarker can be used in multiple drug development programs without a need for CDER to reconfirm the suitability of the biomarker’s qualified context of use and has the potential to advance public health by streamlining the drug development paradigm.
What is the process to qualify a biomarker?
The biomarker qualification process consists of three stages: (1) Initiation, (2) Consultation and Advice, and (3) Review.
Submit a biomarker for qualification
CDER will work collaboratively with submitters through the biomarker qualification process, whether for a single biomarker or for a panel of biomarkers.
Submitters should contact CDER to start the qualification process once they have all of the following:
- A clear understanding of the relationship between a biomarker and the clinical outcome
- A defined use for the biomarker in drug development
- An identified biomarker measurement assay, preferably analytically validated
Information for biomarker qualification submitters
Learn about the biomarker qualification submission process, including the action items, expectations, resources, and tools necessary to qualify a biomarker.
For more information, contact FDA CDER: